本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301047 证券简称：义翘神州 公告编号：2024-006 北京义翘神州科技股份有限公司 关于收到北京证监局行政监管措施决定书的公告 特此公告。 1 北京义翘神州科技股份有限公司（以下简称"公司"）于近日收到中国证券 监督管理委员会北京监管局（以下简称"北京证监局"）出具的《关于对北京义 翘神州科技股份有限公司、冯涛采取出具警示函行政监管措施的决定》（〔2024〕 34 号），现将相关内容公告如下： 公司及相关人员收到上述行政监管措施决定书后，高度重视行政监管措施决 定书中指出的问题，表示将认真总结并吸取教训，切实加强对《上市公司信息披 露管理办法》《深圳证券交易所创业板股票上市规则》等法律法规及规范性文件 的学习，不断提升公司规范运作水平，认真、及时履行信息披露义务，避免此类 事件再次发生，促进公司健康、稳定、持续发展。 一、行政监管措施决定书的内容 本次行政监管措施不会影响公司正常的生产经营管理活动。敬请广大投资者 理性投资，注意投资风险。 "北京义翘神州科技股份有限公司、冯涛： 经查，你公司存在 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）于 2024 年 2 月 2 日 召开第二届董事会第八次会议，审议通过了《关于回购公司股份方案的议案》， 具体内容详见公司于 2024 年 2 月 3 日在巨潮资讯网(www.cninfo.com.cn)上披露 的《关于回购公司股份方案的公告》。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等法律法规、规范性文件的有关规定，现将公司 2024 年第 一次临时股东大会股权登记日（即 2024 年 2 月 5 日）登记在册的前十名股东和 前十名无限售条件股东的名称、持股数量及持股比例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 1 | 拉萨爱力克投资咨询有限公司 | 65,140,056 | 50.42 | | 2 | QM92 LIMITED | 5,968,652 | 4.62 | | 3 | 天津义翘安元企业管理咨询合伙企业 ...

证券代码：301047 证券简称：义翘神州 公告编号：2024-001 北京义翘神州科技股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京义翘神州科技股份有限公司（以下简称"公司"）第二届董事会第八次 会议通知于 2024 年 1 月 30 日以通讯方式送达全体董事，会议于 2024 年 2 月 2 日在公司会议室以现场和通讯方式召开。本次会议应出席董事 9 人，实际出席董 事 9 人，公司部分监事及高级管理人员列席了本次会议。本次会议由董事长谢良 志博士召集并主持，本次会议的召集和召开程序符合《公司法》等法律法规、规 范性文件和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事充分讨论，会议以投票表决方式审议通过了如下议案： 1、逐项审议通过《关于回购公司股份方案的议案》 1.01 回购股份的目的 基于对公司未来发展前景的信心及对公司整体价值的判断，为维护广大投资 者尤其是中小投资者的利益，增强投资者信心，推动公司股票价格向长期内在价 值的合理回归，促进公司稳定可持续发展，在综 ...

重要内容提示： 1、回购股份方案的主要内容 （1）回购股份的种类：公司已发行的人民币普通股（A 股）； 证券代码：301047 证券简称：义翘神州 公告编号：2024-002 北京义翘神州科技股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 （2）回购股份的用途：本次回购股份将用于注销并减少公司注册资本； （3）回购股份的价格区间：不超过人民币 100 元/股（含）； （4）回购股份的实施期限：自公司股东大会审议通过本次回购股份方案之 日起 12 个月内； （5）资金来源：公司自有资金； （6）拟用于回购的资金总额：本次回购资金总额为不低于人民币 10,000 万 元且不超过人民币 20,000 万元（均包含本数），具体回购资金总额以实际使用 的资金总额为准； （7）回购股份的数量及占公司总股本的比例：按回购资金总额上限人民币 20,000 万元、回购价格上限人民币 100 元/股进行测算，预计回购股份数为 200 万股，约占公司当前总股本的 1.55%；按回购资金总额下限人民币 10,000 万元、 回购价格上限人民币 ...

证券代码：301047 证券简称：义翘神州 公告编号：2024-003 北京义翘神州科技股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）于 2024 年 2 月 2 日 召开第二届董事会第八次会议，审议通过了《关于提请召开 2024 年第一次临时 股东大会的议案》，决定于 2024 年 2 月 19 日（星期一）召开 2024 年第一次临 时股东大会。本次股东大会将采用现场投票和网络投票相结合的方式召开，根据 相关规定，现将会议有关事项通知如下： 一、会议召开的基本情况 （一）会议届次：2024 年第一次临时股东大会 （二）会议召集人：公司董事会 （三）会议召开的合法性及合规性：本次股东大会的召开符合有关法律、法 规、规范性文件和《公司章程》的相关规定。 （四）会议召开日期、时间： 1、现场会议时间：2024 年 2 月 19 日（星期一）下午 14:30 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2024 年 2 月 1 ...

北京义翘神州科技股份有限公司 关于控股股东股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）于近日收到公司控股 股东拉萨爱力克投资咨询有限公司（以下简称"爱力克"）的通知，获悉其所持 有公司的股份办理了解除质押业务，具体事项如下： 一、本次解除质押基本情况 | 股东 | 是否为控股股 东或第一大股 | 本次解除质押 | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其一致行 | 股份数量（股） | （%） | （%） | | | | | | 动人 | | | | | | | | 爱力克 | 是 | 7,500,000 | 11.51 | 5.80 | 2022.7.25 | 2023.11.29 | 西藏信托有限公司 | 证券代码：301047 证券简称：义翘神州 公告编号：2023-056 北京义翘神州科技股份有限公司董事会 2023 年 ...

证券代码：301047 证券简称：义翘神州 公告编号：2023-055 北京义翘神州科技股份有限公司 注册资本：人民币 12,920 万元 成立日期：2016 年 12 月 22 日 法定代表人：张杰 住所：北京市北京经济技术开发区景园街 8 号院 1 号楼 9 层 B901 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）分别于 2023 年 4 月 21 日、2023 年 5 月 15 日召开第二届董事会第二次会议、2022 年年度股东大会， 审议通过了《关于变更注册地址、经营范围及修订<公司章程>的议案》，具体 内容详见公司 2023 年 4 月 22 日、2023 年 5 月 15 日披露于巨潮资讯网 （www.cninfo.com.cn）的相关公告。 近日，公司完成了工商变更登记、《公司章程》备案等手续，并取得了北京 经济技术开发区市场监督管理局颁发的《营业执照》，相关信息如下： 名称：北京义翘神州科技股份有限公司 类型：股份有限公司（港澳台投资、上市） 统一社 ...

Financial Performance - Revenue for the first three quarters of 2023 reached 476 million yuan, a year-on-year increase of 10.64% [4] - Regular business revenue for the first three quarters of 2023 was 356 million yuan, a year-on-year increase of 17.94% [4] - Revenue for the third quarter of 2023 was 184 million yuan, a year-on-year increase of 40.23% [4] - Regular business revenue for the third quarter of 2023 was 124 million yuan, a year-on-year increase of 11.40% [4] Business Operations - The company focuses on independent development and improving technical capabilities to provide high-quality reagents and services for global life science research and biopharmaceutical innovation [4] - The company's acquisition of SignalChem Biotech (SCB) aims to enhance its product portfolio and global market presence, particularly in North America [5] - SCB, a Canadian biotech company, specializes in high-quality enzyme protein products and has a strong market position in the kinase field [5] - The company's cytokine products have seen significant development and market expansion, with increased investment and product upgrades in 2023 [5] Research and Development - R&D expenses in 2023 have increased significantly compared to the previous year, with a focus on protein and antibody-related new product development, membrane protein research, and platform construction [5] - The company plans to maintain a high level of R&D investment in the near future to ensure competitive strength [5] Investor Relations - The company held an investor relations event on October 27, 2023, attended by representatives from various securities firms, asset management companies, and investment firms [2][3] - Key topics discussed during the event included the company's financial performance, business operations, and future outlook [4][5]

Government Subsidies and Income - Government subsidies recognized in the current period amounted to ¥449,524.98, with a total of ¥3,429,153.38 from the beginning of the year to the end of the reporting period[4] - The fair value changes and investment income from trading financial assets and liabilities generated a profit of ¥15,735,504.38 for the current period, totaling ¥76,641,191.91 year-to-date[4] - Other operating income and expenses, excluding the above items, generated a profit of ¥345,026.07, with a total of ¥380,421.09 year-to-date[4] - The total profit after tax for the current period was ¥14,050,547.11, with a cumulative total of ¥68,383,151.42 for the year[4] Financial Position - As of September 30, 2023, cash and cash equivalents amounted to ¥2,576,126,825.44, an increase from ¥2,379,661,988.27 at the beginning of the year[12] - Trading financial assets decreased to ¥2,179,371,298.16 from ¥3,422,367,143.67 at the beginning of the year[12] - Accounts receivable increased to ¥175,132,423.28 from ¥140,385,288.86 at the beginning of the year[12] - Total assets as of September 30, 2023, were ¥6,502,123,624.31, down from ¥6,570,390,331.09 at the beginning of the year[12] - Non-current assets totaled ¥1,486,125,495.54, significantly up from ¥546,416,173.11 at the beginning of the year[12] - Current liabilities, specifically accounts payable, decreased to ¥17,839,343.48 from ¥29,230,336.08 at the beginning of the year[12] - The total assets at the end of the reporting period amounted to ¥6,502,123,624.31, down 1.04% from the end of the previous year[22] - The company's total liabilities decreased to ¥192,959,228.90, down from ¥201,007,464.00 in the previous year[22] - The company's equity attributable to shareholders decreased slightly to ¥6,309,164,395.41, a 0.95% decline from the previous year[22] Revenue and Profitability - The company's operating revenue for the current period reached ¥183,683,658.18, representing a 40.23% increase year-over-year[22] - The net profit attributable to shareholders for the current period was ¥69,537,875.14, a decrease of 16.93% compared to the same period last year[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥55,487,328.03, reflecting a 35.14% increase year-over-year[22] - Total operating revenue for the period reached ¥476,061,706.26, an increase from ¥430,286,790.03 in the previous period, representing an increase of approximately 10.0%[37] - Total operating costs amounted to ¥311,276,926.31, up from ¥197,617,410.06, indicating a significant increase of approximately 57.4%[38] - Operating profit decreased to ¥234,562,224.77 from ¥322,168,393.07, reflecting a decline of about 27.2%[38] - Net profit for the period was ¥205,197,148.65, down from ¥275,901,898.54, representing a decrease of approximately 25.5%[38] - The company reported a financial income of ¥37,759,118.82, down from ¥48,675,417.36, indicating a decrease of approximately 22.0%[38] - The company reported a net profit attributable to shareholders of 205,197,148.65 CNY, compared to 275,901,898.54 CNY in the previous period, reflecting a decrease of approximately 25.5%[39] - The total comprehensive income for the period was 196,081,756.32 CNY, down from 265,548,182.68 CNY, indicating a decline of about 26.1%[39] - The basic earnings per share (EPS) was 1.5882 CNY, compared to 2.5359 CNY in the previous period, representing a decrease of approximately 37.3%[39] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥176,607,352.76, showing a 3.96% increase[22] - Investment activities generated a net cash flow of ¥263,584,700.54, a significant increase of 1346.08% compared to the previous period[31] - Financing activities resulted in a net cash flow of -¥274,866,085.20, a decrease of 60.35% from -¥693,261,769.57 in the previous period[31] - Operating cash flow for the period was 176,607,352.76 CNY, an increase of 3.96% from 169,882,187.35 CNY year-over-year[50] - The net cash flow from investment activities was 263,584,700.54 CNY, recovering from a negative cash flow of -21,153,032.57 CNY in the previous period[40] - The company experienced a net cash outflow from financing activities of 274,866,085.20 CNY, compared to a larger outflow of 693,261,769.57 CNY in the previous period[41] Research and Development - Research and development expenses increased by 55.18% to ¥61,037,480.06, driven by the expansion of the R&D team[29] - Research and development expenses increased to ¥61,037,480.06 from ¥39,332,093.12, marking an increase of approximately 55.0%[38] Shareholder Information - The company had a total of 24,921 common shareholders at the end of the reporting period[31] - The largest shareholder, Lhasa Ailike Investment Consulting Co., Ltd., holds 50.42% of the shares, amounting to 65,140,056 shares[31]